LncRNA PRKCQ-AS1 was markedly upregulated in tamoxifen-resistant tumor samples and was associated with poor prognosis in tamoxifen-treated ER + breast cancer patients but not in those treated with aromatase inhibitors. Here, CYP19A1 is linked to breast carcinoma.